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Abstract
Purpose PET/MR has the potential to become a powerful
tool in clinical oncological imaging. The purpose of this
prospective study was to evaluate the performance of a
single T1-weighted (T1w) fat-suppressed unenhanced MR
pulse sequence of the abdomen in comparison with unen-
hanced low-dose CT images to characterize PET-positive
lesions.
Methods A total of 100 oncological patients underwent se-
quential whole-body 18F-FDG PETwith CT-based attenuation
correction (AC), 40 mAs low-dose CT and two-point Dixon-
based T1w 3DMRI of the abdomen in a trimodality PET/CT-
MR system. PET-positive lesions were assessed by CT and
MRI with regard to their anatomical location, conspicuity and
additional relevant information for characterization.
Results From among 66 patients with at least one PET-
positive lesion, 147 lesions were evaluated. No significant
difference between MRI and CT was found regarding ana-
tomical lesion localization. The MR pulse sequence used
performed significantly better than CT regarding conspicu-
ity of liver lesions (p<0.001, Wilcoxon signed ranks test),
whereas no difference was noted for extrahepatic lesions.
For overall lesion characterization, MRI was considered
superior to CT in 40 % of lesions, equal to CT in 49 %,
and inferior to CT in 11 %.
Conclusion Fast Dixon-based T1w MRI outperformed low-
dose CT in terms of conspicuity and characterization of
PET-positive liver lesions and performed similarly in extra-
hepatic tumour manifestations. Hence, under the assumption
that the technical issue of MR AC for whole-body PET
examinations is solved, in abdominal PET/MR imaging
the replacement of low-dose CT by a single Dixon-based
MR pulse sequence for anatomical lesion correlation
appears to be valid and robust.
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Introduction
Integrated PET/CT systems have been successfully imple-
mented in clinical workflow—particular in oncology—since
their introduction approximately one decade ago [1, 2]. The
integration of functional and anatomical information in
PET/CT with low-dose CT at 40 mAs has resulted in sig-
nificant improvements in lesion localization and classifica-
tion compared to PET imaging alone [2].
Recently several groups have started to study the possi-
bility of replacing CT by MR in PET/MR systems. Integrat-
ed PET/MR opens new perspectives in biomedical research
and clinical multimodality imaging [3–6]. In addition to
better soft tissue contrast and lack of ionizing radiation
exposure, MRI offers a wide range of advanced imaging
techniques [7, 8], such as apparent diffusion coefficient
maps for quantification of cellular density [9], arterial spin
labelling for measurement of blood flow [10], dynamic
contrast enhancement to assess the characteristics of tumour
vasculature, including perfusion, blood vessel permeabil-
ity, blood volume and extravascular extracellular volume
fraction [11], and quantification of tissue metabolite
concentrations by calibrated 1H-MR spectroscopy [12,
13] or based on hyperpolarized 13C [14]. Hence, multi-
parametric PET/MR has the potential to become a pow-
erful tool for accurate primary diagnosis and early
evaluation of therapy response.
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In a clinical setting the cost-effectiveness of an inte-
grated multimodality scanner is of major importance
[15]. Most of the advanced MR imaging techniques
are time-consuming, and therefore limited to a body
region of particular interest, while integrated PET/CT
imaging in oncological patients typically surveys a
much larger part of the body. In addition to detecting
distant metastases, PET/CT can also detect second pri-
mary tumours, e.g. in head and neck cancer, and has
therefore a major impact on patient management [16].
Full coverage of the PET field of view (FOV) with a
fast and robust MR pulse sequence is therefore neces-
sary in oncology patients to provide anatomical correla-
tion similar to that achieved with a low-dose CT scan
[17]. Furthermore, this survey MR pulse sequence
should ideally also provide data for anatomical MR-
based attenuation correction (AC) of PET data equiva-
lent to that provided by CT. Currently, the proposed
approaches for MR AC in torso imaging are mainly
based on tissue segmentation, pattern recognition tech-
niques, templates or atlases [18–23]. Apart from lesions
in bone [24] and in the skull [25, 26], MR AC based
on such techniques has been shown to yield comparable
results to CT AC of PET data.
The purpose of this prospective study was to com-
pare a single T1-weighted (T1w) fat-suppressed MR
pulse sequence of the abdomen without administration
of contrast medium acquired in the axial plane with
low-dose CT images without administration of contrast
medium. The latter are acquired in our routine PET/CT
protocols. Comparison was made in terms of anatomical
localization, lesion conspicuity and characterization of
PET-positive lesions.
Materials and methods
Patient population
A total of 100 adult patients (49 men, 51 women; mean age
59 years, range 21–78 years) were enrolled in this prospec-
tive study. All patients were referred for a clinical 18F-FDG
PET/CT examination for either staging or restaging/follow-
up of various malignant tumours. Exclusion criteria were
unwillingness to undergo an additional MR examination,
claustrophobia, MR-incompatible medical devices (e.g. car-
diac pacemaker, insulin pump, neurostimulator, cochlear
implant), possible metallic fragments in the body or a body
habitus (e.g. excessively obese patients) such that the patient
would not have fitted into the relatively confined MR gantry
due to the specially mounted surface coils (see below). This
study was approved by the institutional ethics committee
and written informed consent was obtained from all patients.
PET/CT and MR imaging
Sequential PET/CT and MR imaging was performed on a
trimodality PET/CT-MR setup (full-ring, time-of-flight Dis-
covery PET/CT 690 and a 3-T Discovery MR 750; both GE
Healthcare, Waukesha, WI). All patients were positioned on
a shuttle board which was placed on top of either the PET/
CT table or the MR table. A mechanism able to transfer the
shuttle board from one to the other table ensured that patient
transport from the PET/CT to the MR system and place-
ment/removal of dedicated radiofrequency (RF) coils were
possible without repositioning the patient. The shuttle board
had caudal space holders permitting insertion and removal
of the posterior coil components without having to move the
patient, but added approximately 7 cm to the table height,
which resulted in a restricted AP diameter bore available for
patient placement in the MR scanner. The RF coils used
enabled fast and high signal-to-noise MR coverage and the
special shuttle transport board enabled PET/CT scanning
free of coil-induced artefacts.
PET/CT was performed according to the EANM proce-
dure guidelines for tumour PET imaging [27]. Patients
fasted for at least 4 h prior to injection of a standard dose
of approximately 350 MBq of 18F-fluorodeoxyglucose
(FDG). After a standardized uptake time of 60 min (range
58–62 min), unenhanced low-dose CT and PET emission
data were acquired from the mid-thigh to the vertex of the
skull. CT data were acquired in breath-hold with 50–80 mA/
slice, 120 kVp, a pitch of 0.984:1, a collimation of 64×
0.625 mm, a measured FOV of 50 cm, a noise index of
20 %, reconstructed to images of 0.625 mm transverse pixel
size and 3.75 mm slice thickness. PET data was acquired in
3D time-of-flight mode with a scan duration of 2 min per
bed position, an axial FOVof 153 mm and a 23 % overlap of
bed positions, resulting in a total PET acquisition time of
12 min. The emission data were corrected for randoms, dead
time, scatter and attenuation and iteratively reconstructed
(three iterations, 18 subsets) using the CT data. After shuttle
transfer to the MR system and placement of the dedicated
RF coil (32 channel torso coil; GE Healthcare, Waukesha,
MI) an axial two-point Dixon-based T1w 3D gradient echo
sequence (LAVA-Flex; GE Healthcare) was performed and
water images were reconstructed. The scanning parameters
were 48 cm FOV with 80 % phase FOV, 320×256 acquisi-
tion matrix, 6.8 mm slice thickness with slice overlap of
3.4 cm and a reconstructed voxel size of 1.5×1.5×3.4 mm,
3.8 ms repetition time (TR), 1.7 ms echo time (TE), 13° flip
angle, 781.25 Hz pixel bandwidth, 0.7 number of excita-
tions (NEX), and parallel imaging acceleration factor 2
using k-space-based autocalibrating reconstruction for Car-
tesian imaging (ARC; GE Healthcare). Scan duration was
16 s for coverage of an axial FOV of 200 mm with image
acquisition in breath-hold mode. The scan covered the
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abdomen as well as the lower parts of the chest (two adja-
cent axial FOVs). No intravenous contrast agent was admin-
istered, either for the MR or the CT studies.
Image processing
The PET, CT and MR images acquired were sent to a
dedicated review workstation (Advantage workstation, ver-
sion 4.5; GE Healthcare, Milwaukee, WI) which allows
simultaneous review of PET, CT and MR images side by
side or in fused/overlay mode (PET/CT, PET/MR). Due to a
fixed table height of the PET/CT and MR system and
consistent laser light landmarking on the top of the longitu-
dinal transfer table, no software-based image registration
was necessary.
Image analysis
All images were analysed by two double board-certified
nuclear medicine physicians/radiologists. The analysed
axial abdominal images included the basal parts of the
chest.
Detection of PET-positive lesions First, each PET examina-
tion was evaluated for the presence of PET-positive lesions
within the body area covered by the abdominal MRI scan.
Patients without any PET-positive lesions in this area were
excluded from further evaluation. Lesions were considered
PET-positive if their maximum standardized uptake value
(SUVmax; corrected for body weight) was at least double
that of the surrounding background activity. The threshold
value as percentage of SUVmax was manually adjusted for
each lesion such that the borders of the volume of interest
only included activity that could be ascribed to tumour. Up
to eight PET-positive lesions were evaluated per patient with
a maximum of three lesions per single organ/structure [28].
In patients with multiple lesions in the same organ (e.g.
disseminated liver metastases), lesions that were clearly
distinguishable from each other were selected for analysis.
Lesions were selected in consensus to make sure that both
readers evaluated the same lesions. This was done jointly by
the two readers.
Image quality assessment As the next step each reader
had to classify the axial CT image and the MR image
section at the level of the PET-positive lesion in terms
of image artefacts using a three-point scale: grade 0 (no
artefacts), grade 1 (mild artefacts but still sufficient
image quality for correct anatomical assignment), grade
2 (substantial artefacts with image quality insufficient
for correct anatomical assignment of PET-positive
lesions). This assessment was done independently by
the two readers.
Anatomical assignment of PET-positive lesions Each reader
individually and independently had to note the anatomical struc-
ture corresponding to the PET-positive lesion based on the
combination of the PETand CT data and the PETandMR data.
Lesion conspicuity Lesion conspicuity was assessed based
on a three-point scale: grade 0 (complete delineation), grade
1 (partial delineation), grade 2 (not detectable).
Lesion characterization Each reader had to decide if the CT
or the MR scan provided more relevant information for
lesion characterization in combination with the PET data.
A value of 1 was assigned when the MR scan provided more
relevant information than the CT scan (e.g. better delinea-
tion of liver lesion extent or determination of the affected
liver segment not visible on the unenhanced low-dose CT
scan). A value of −1 was assigned when the CT scan pro-
vided more information than the MR scan (e.g. presence of
air bubbles not visible on the MRI scan in a PET-positive
lesion suggestive of an inflammatory process). A value of 0
was assigned when both the CT scan and the MR scan
provided the same amount of information.
Lesion size As a last step, measurements of the maximum
lesion diameters on CT and MR images and of the metabolic
lesion volumes were obtained in consensus. Lesions not
visible on the CT or MR images were not measured in that
particular modality and noted as “not measurable”.
Statistical analysis
All statistical tests were performed using the IBM SPSS
Statistics, version 19.0, software package for Microsoft
Windows. Statistical significance was assumed for p values
less than 0.05. The Wilcoxon signed ranks test was used for
intraobserver comparisons of lesion conspicuity ratings for
CT vs. MR images and for comparisons of lesion diameter
measurements on CT and MR images from the consensus
reading. The Cohen κ statistic was used to evaluate interob-
server agreement for anatomical assignment of PET-positive
lesions and for lesion conspicuity, and for the question as to
whether low-dose CT or Dixon-based MRI provided more
relevant information for PET-positive lesion characteriza-
tion. According to Landis and Koch [29], κ values smaller
than 0.20 indicate poor agreement, and values in the ranges
0.21–0.40, 0.41–0.60, 0.61–0.80 and 0.81–1.00 indicate
fair, moderate, good and very good agreement, respectively.
Results
Detection of PET-positive lesions Of the 100 patients exam-
ined with sequential PET/CT and MRI, 66 (33 men, 33
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women; mean age 60 years, range 21–78 years) showed at
least one PET-positive lesion in the body area covered by the
abdominal MRI, and were remained for further evaluation. A
total of 147 PET-positive lesions were evaluated. How many
patients not willing or not able to undergo anMR examination
was not determined. Quantitative PET measurements yielded
a median metabolic volume of 3.0 ml (range 0.2–431 ml) and
a mean SUVmax of 11.9 (range 3.0–52.0). The primary
malignancies in these 66 patients were lung cancer (12
patients, 18.2 %), colon cancer (11 patients, 16.7 %), pancre-
atic cancer (6 patients, 9.1 %), breast cancer (5 patients,
7.6 %), Hodgkin’s lymphoma (5 patients, 7.6 %), non-
Hodgkin’s lymphoma (2 patients, 3.0 %), rectal cancer (4
patients, 6.1 %), malignant melanoma (4 patients, 6.1 %),
stomach cancer (3 patients, 4.5 %), pleural mesothelioma (3
patients, 4.5 %), oesophageal cancer (2 patients, 3.0 %) and
gastrointestinal stromal tumour (2 patients, 3.0%). There were
also seven patients with a primary tumour located in the
hypopharynx, parotid gland, thyroid, biliary tract, adrenal
gland, kidney, and anus (each 1.5 %).
Image quality assessment Neither of the two readers
reported substantial (grade 2) artefacts in the low-dose CT
images for the corresponding image sections where the 147
PET-positive lesions were best visualized. For the
corresponding MR images substantial (grade 2) artefacts
were reported in 3 of 147 image sections (2.0 %) and in 1
of 147 image sections (0.7 %) by the two readers, respec-
tively. The mean frequencies of mild artefacts on MR
images and low-dose CT images were 19.5 % and 9 %,
respectively.
Anatomical assignment of PET-positive lesions Interob-
server agreement for anatomical assignment of PET-positive
lesions to a specific organ/structure was very good for PET/
CT (κ00.95) and for PET/MR (κ00.89). Furthermore, there
was very good interobserver agreement between PET/CT
assignments of reader 1 and PET/MR assignments of reader
2 and vice versa (κ00.93 and 0.89, respectively). Anatomical
assignment remained inconclusive for three PET-positive
lesions considered “not measurable” on CT images and for
two lesions considered “not measurable” on MRI images,
respectively.
Comparison between lesion conspicuity and lesion size The
conspicuity of liver lesions was better on MR images than
on CT images (n051; p<0.001, Wilcoxon signed ranks
test). For lung lesions (n014), one reader found MRI to be
inferior to CT (p00.046). For all other lesions no significant
differences were found between MR images and CT images
(Table 1). Single lesions in the breast, oesophagus, small
intestine, paracolic space, spleen and peritoneum were not
considered in this evaluation. Interobserver agreement on
lesion conspicuity was good for CT (κ00.72) and fair for
MR (κ00.46).
Morphologically measurable lesions No statistically signif-
icant difference in lesion diameter was found between low-
dose CT and MR images (p00.472, Wilcoxon signed ranks
test). The median largest lesion diameter was 19 mm (range
5–101 mm) for CT images and 18 mm (range 4–123 mm)
for MR images.
Lesions “not measurable” Of the 147 PET-positive
lesions, 52 (35.4 %) and 26 (17.7 %) were not visible
on low-dose CT images and MR images, respectively.
These lesions were located in the following anatomical
structures: liver (CT/MRI: 30/2), bone (6/9), colon (4/4),
Table 1 Intraobserver compari-
son of PET-positive lesion con-
spicuity on corresponding T1w
fat-suppressed unenhanced MR
images and unenhanced low-
dose CT images
aThe sum of all lesions is greater
than 147 because lesions were
compared when at least one
reader indicated a lesion in a
particular organ/anatomical
structure in at least one modality
(CT or MR). This was done to
circumvent the subjective aspect
of a consensus reading.
bWilcoxon signed ranks test; p
values<0.05 were considered
significant.
Lesion location Number of lesionsa Reader 1 Reader 2
Conspicuity rating p valueb Conspicuity rating p valueb
Liver 51 MR > CT <0.001 MR > CT <0.001
Bone 26 MR 0 CT 0.701 MR 0 CT 0.976
Lymph nodes 23 MR 0 CT 0.317 MR 0 CT 0.257
Lung 14 MR 0 CT 0.317 MR < CT 0.046
Pleura 8 MR 0 CT 0.102 MR 0 CT 0.414
Soft tissue 8 MR 0 CT 0.180 MR 0 CT 0.317
Chest wall 6 MR 0 CT 0.450 MR 0 CT 0.713
Adrenal glands 5 MR 0 CT 0.317 MR 0 CT 0.317
Pancreas 4 MR 0 CT 0.180 MR 0 CT 0.317
Stomach 4 MR 0 CT 0.317 MR 0 CT 0.317
Colon 4 MR 0 CT 1.000 MR 0 CT 1.000
Unclear 4 MR 0 CT 0.317 MR 0 CT 0.317
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stomach (4/3), pancreas (3/2), lung (1/2), adrenal gland
(1/1), pleura (1/1), paracolic space (1/1), muscle (0/1),
chest wall (1/0); 19 lesions (12.9 %) were not measur-
able on both CT and MR images.
Interobserver comparison of lesion characterization Re-
garding the question as to whether low-dose CT or MRI pro-
videdmore relevant information for the overall interpretation of
the 147 PET-positive lesions (including anatomical location,
conspicuity, infiltration of adjacent structures, additional imag-
ing features helpful to increase diagnostic confidence), MRI
was considered superior to CT in 40 % of the lesions, equal to
CT in 49 % and inferior to CT in 11 % (mean values of the two
readers). Interobserver agreement was good (κ00.70). The
superiority of MRI over low-dose CT for overall interpretation
of liver lesions had amajor impact on these results. Considering
only the 99 extrahepatic lesions, MRI was superior to CT in
20 % of the lesions, equal to CT in 65 % and inferior to CT in
15 %. The results of this evaluation are illustrated in Fig. 1.
Discussion
In this study we showed that a fast axial two-point
Dixon-based T1w 3D gradient echo MR sequence (LA-
VA-Flex; 16 s/200 mm in breath-hold, no intravenous
contrast agent) provided similar clinical information to a
nonenhanced 40-mAs low-dose CT scan with respect to
anatomical mapping, lesion conspicuity and character-
ization of extrahepatic abdominal PET-positive lesions.
In PET-positive liver lesions coregistered PET and unen-
hanced MR images outperformed unenhanced PET/CT.
These results are in line with those of Eiber et al. [17]
who used Dixon-based MR sequences (volumetric inter-
polated breath-hold examination) in comparison with a
20-mAs low-dose CT scan for anatomical correlation
and delineation of PET-positive findings. However, there
are important differences between the studies:
1. In the present study MR pulse sequences were compared
with a 40-mAs low-dose CT scan as routinely used as a
first step in PET/CT in many institutions. It was shown in
the early PET/CT literature that unenhanced CT up to
40 mAs improves lesion characterization compared to
PET alone, but no further improvement is achieved by
increasing the mAs of the CT scan [2].
2. Our system permitted sequential PET, CT and MR image
acquisition using a patient shuttle system which avoided
the need for patient repositioning between the PET/CT
into PET/MR systems and vice versa. For comparative
image analysis the CT and the MR images were automat-
ically coregistered with a single PET dataset rather than
two PET datasets as are generated in studies where PET/
MR only systems are used (PET1/CT vs. PET2/MR).
Fig. 1 Average ratings of the two readers as to whether CT or MRI
provided more relevant information for the anatomical localization,
delineation and characterization of PET-positive lesions. The thickness
of the bars indicates the number of lesions available for evaluation.
Structures where fewer than four PET-positive lesions were found in
total are not included in this illustration. The unexpected superiority of
MRI over CT in the lung can be explained by the fact that three patients
showed mediastinal (two patients) or a chest wall (one patient) lesion
or infiltration with better conspicuity on MR images, while other
pulmonary lesions were visible on images of either modality. One
metastatic lesion in the right adrenal was better visualized on CT than
on MR images
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3. Due to the small number of patients in the study by Eiber
et al. [17], the number of organ-specific lesions was not
high enough for statistical analysis comparing low-dose
CTand Dixon-MRI. Our larger and prospective study was
able to provide statistically significant information.
MR image quality was found to be robust with only about
1–2 % nondiagnostic datasets. Regarding the crucial breath-
hold during MR image acquisition, 16 s of breath-hold
seemed to be achievable by most patients. This robustness of
image quality renders the applied Dixon-MR sequence also a
potentially reliable sequence for MR AC based on tissue
segmentation, pattern recognition techniques, templates or
atlases. Both MR and CT were similar in their ability to
anatomically localize PET-positive lesions. The relatively
low interobserver agreement for MR lesion conspicuity was
caused by diverging judgements as to whether a lesion was
partly or completely delineated. Using a two-point scale in-
stead (not visible vs. visible) the interobserver agreement was
very good (κ00.89). A relatively high number of PET-
positive lesions were considered “not measurable” on CT
images (35.4 %), whereas on MRI only 17.7 % of the lesions
were considered “not measurable”. Again, this difference was
mainly caused by liver lesions not visible on unenhanced CT
images. The better performance of MRI in liver imaging was
primarily due to the high MR soft tissue contrast. This advan-
tage enabled better delineation of small liver lesions as well as
reliable localization of lesions to the corresponding liver seg-
ment (Fig. 2). Regarding the slight superiority of CT for lung
lesions it has to be noted that only PET-positive lesions were
assessed. Thus, only 2 of 14 lung lesions in this evaluation
were smaller than 1 cm. Themean diameter of the lung lesions
on CT images was 14.6 mm (range 5–62 mm). MR tended to
perform better for the determination of tumour infiltration into
the chest wall or the mediastinum (Fig. 3).
For the prospective detection of very small lung nodules it is
generally accepted that CT performs better. However, different
new imaging strategies might yield an applicable dedicated
MR sequence capable of also identifying smaller lung nodules
[30]. In our study CT and MRI performed similarly in charac-
terizing bone lesions. However, CT enabled the evaluation of
lytic bone destruction and consequently allowed better assess-
ment of the fracture risk. In the future, ultrashort echo time
Fig. 2 A 52-year-old male patient suffering from metastasizing ma-
lignant melanoma: unenhanced low-dose CT image (a), T1w fat-
suppressed MR image (b), fused 18F-FDG PET/CT image (c), PET/
MR image (d). In MRI melanin shortens the T1 relaxation time and
therefore appears hyperintense on T1w images. This enables precise
lesion delineation on MR images as seen in the liver (arrowheads), in
the stomach wall (arrows) and in a coeliac lymph node (circle)
Fig. 3 A 70-year-old male patient with newly diagnosed non-small
cell bronchial carcinoma in the right lower lobe referred for tumour
staging: axial 18F-FDG (a) image with corresponding unenhanced low-
dose CT image in soft tissue (b) and lung window (d), T1w fat-
suppressed MR image (c), fused PET/CT image (e), fused PET/MR
image (f). Mediastinal tumour infiltration was assumed on both the CT
image (c) and MR image (d). However, in comparison with low-dose
CT image (b), tumour conspicuity on the MR image (c, arrowheads) in
relation to the aorta (AO) and to the oesophagus (arrows) is slightly
better
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sequences might be an option to gain such information using
MRI [25, 26]. In the delineation of lymph nodes, no tendency
for better performance ofMRI over CTwas found. A relatively
high in-plane resolution and fat suppression supported lymph
node detection on MR images.
Limitations
In this study only the fat-suppressed images of the two-point
Dixon MR sequence were evaluated, because our aim was to
investigate the diagnostic potential of a single fast MR se-
quence as a potential replacement for low-dose CT in the
abdomen. Information provided by in-phase, out-of-phase and
fat-only images of the Dixon MR sequence can be used as an
additional benefit. Easy detection of fat replacement by tumour
tissue might help distinguish benign from malignant lesions in
bone, adrenal glands or liver with a higher accuracy [31].
It is important to note that the results of this study cannot be
extrapolated to other body parts, i.e. chest or head and neck.
The diagnostic potential of a single fast MR sequence in these
regions needs evaluating in further studies. Furthermore (and
as stated at the outset), on the basis of the data presented here
we cannot make any statements with regard to the benefits of
MR AC over CT AC, but rather assume that eventually MR
AC will be possible. Finally, the access of the two readers to
CT and MR images at the same time might have induced a
bias to the results. However, this direct side-by-side compar-
ison ensured that the same PET-positive lesions were morpho-
logically characterized on the CT and MR images.
Conclusion
In this prospective study coregistered PET (using CT for
PET attenuation and scatter correction) and unenhanced fast
MR imaging (using a single Dixon-based MR sequence)
out-performed unenhanced PET/CT with a 40 mAs low-
dose CT scan for anatomical localization, conspicuity and
characterization of PET-positive liver lesions. For extrahe-
patic PET-positive abdominal lesions the PET and MR com-
bination and the PET and CT combination were found to
perform comparably, even in the basal parts of the lung,
which might be the most challenging organ for MR to match
CT in hybrid PET imaging. Hence, in abdominal PET im-
aging the replacement of low-dose CT by a single Dixon-
based MR sequence appears to be valid and robust for the
assessment of PET-positive lesions. This short imaging se-
quence provides the ability to survey extended body parts in
times comparable to those needed for a PET survey. It may
therefore become the preferred MR pulse sequence to be
acquired in parallel with PET in a PET/MR scanner capable
of simultaneous PET and MR data acquisition.
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